Skip to main content

Table 1 Blood collection plan

From: A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia

Sample

(Blood)

Volume (mL)

Cycle

Day

Sample No.

Scheduled time relative to BEZ235 dosing post-dose (hours)

 

3

1

1

1

Pre-dose

    

2

1 h post-dose

 

3

1

1

3

2 h post-dose

 

3

1

1

4

3 h post-dose

    

5

5 h post dose

 

3

1

1

6

8–12 h post-dose

(optional)

3

1

2

7

24 h post-dose (trough)

 

3

1

15

8

Pre-dose

 

3

1

15

9

1 h post-dose

 

3

1

15

10

3 h post-dose

 

3

1

15

11

5 h post-dose

(optional)

3

1

15

12

8–12 h post-dose

  1. Blood sample collection plan in the BEZ 235 phase I trial for PK and PD analysis is shown